

Mattheos Bobos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/317110/publications.pdf>

Version: 2024-02-01

127
papers

2,547
citations

236612

25
h-index

223531

46
g-index

129
all docs

129
docs citations

129
times ranked

4087
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunohistochemical Distinction Between Merkel Cell Carcinoma and Small Cell Carcinoma of the Lung. <i>American Journal of Dermatopathology</i> , 2006, 28, 99-104.	0.3	235
2	Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. <i>Annals of Oncology</i> , 2012, 23, 427-435.	0.6	220
3	Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 447-456.	1.1	169
4	A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 1009-1021.	1.1	85
5	Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study. <i>BMC Cancer</i> , 2008, 8, 234.	1.1	84
6	Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 353-362.	1.1	82
7	Gemcitabine Combined with Gefitinib in Patients with Inoperable or Metastatic Pancreatic Cancer: A Phase II Study of the Hellenic Cooperative Oncology Group with Biomarker Evaluation. <i>Cancer Investigation</i> , 2008, 26, 784-793.	0.6	66
8	A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 649-660.	1.1	61
9	Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel. <i>PLoS ONE</i> , 2012, 7, e37946.	1.1	54
10	Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. <i>Oncotarget</i> , 2016, 7, 5074-5087.	0.8	54
11	Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 609-619.	1.1	48
12	Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 245-255.	1.1	48
13	HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. <i>Journal of Translational Medicine</i> , 2012, 10, 10.	1.8	46
14	Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy. <i>BMC Cancer</i> , 2009, 9, 339.	1.1	41
15	Detection of <i>Helicobacter pylori</i> in raw bovine milk by fluorescence in situ hybridization (FISH). <i>International Journal of Food Microbiology</i> , 2011, 151, 252-256.	2.1	41
16	Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer. <i>Oncology</i> , 2009, 76, 275-285.	0.9	37
17	Prognostic utility of β -tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 179-193.	1.1	36
18	Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer. <i>ESMO Open</i> , 2019, 4, e000474.	2.0	34

#	ARTICLE	IF	CITATIONS
19	Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab. <i>Journal of Translational Medicine</i> , 2012, 10, 212.	1.8	32
20	EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 737-748.	1.2	30
21	TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. <i>Oncotarget</i> , 2016, 7, 32731-32753.	0.8	30
22	MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. <i>Journal of Oncology</i> , 2009, 2009, 1-17.	0.6	29
23	Second primary melanomas in a cohort of 977 melanoma patients within the first 5 years of monitoring. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 398-406.	0.6	29
24	Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. <i>BMC Cancer</i> , 2013, 13, 163.	1.1	27
25	The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping. <i>Breast</i> , 2014, 23, 234-243.	0.9	26
26	Evaluation of FISH image analysis system on assessing HER2 amplification in breast carcinoma cases. <i>Breast</i> , 2008, 17, 80-84.	0.9	25
27	A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. <i>Journal of Neurology</i> , 2013, 260, 1469-1480.	1.8	25
28	Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 636-645.	1.0	25
29	MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer. <i>Journal of Translational Medicine</i> , 2016, 14, 136.	1.8	25
30	Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. <i>Anticancer Research</i> , 2011, 31, 3007-18.	0.5	25
31	Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility. <i>Anticancer Research</i> , 2012, 32, 1273-81.	0.5	25
32	Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 77.	3.5	23
33	Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients. <i>BMC Clinical Pathology</i> , 2013, 13, 1.	1.8	23
34	Prognostic significance of the Wnt pathway in squamous cell laryngeal cancer. <i>Oral Oncology</i> , 2014, 50, 298-305.	0.8	23
35	Sialadenoma papilliferum of bronchus. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2003, 443, 695-699.	1.4	22
36	Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 533-546.	1.1	22

#	ARTICLE	IF	CITATIONS
37	A rare tumoral combination, synchronous lung adenocarcinoma and mantle cell lymphoma of the pleura. <i>World Journal of Surgical Oncology</i> , 2008, 6, 137.	0.8	21
38	Sarcoidosis-like granulomatosis of the hypopharynx as a complication of anti-TNF therapy. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2013, 34, 268-272.	0.6	21
39	In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients. <i>PLoS ONE</i> , 2014, 9, e99131.	1.1	21
40	Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression. <i>Anticancer Research</i> , 2014, 34, 4949-62.	0.5	21
41	Identification and validation of gene expression models that predict clinical outcome in patients with early-stage laryngeal cancer. <i>Annals of Oncology</i> , 2012, 23, 2146-2153.	0.6	20
42	Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer. <i>PLoS ONE</i> , 2018, 13, e0208221.	1.1	19
43	Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a case. <i>Dermatologic Therapy</i> , 2021, 34, e14618.	0.8	19
44	Primary pancreatic anaplastic large cell lymphoma, ALK negative: A case report. <i>World Journal of Gastroenterology</i> , 2005, 11, 6221.	1.4	19
45	Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study. <i>Journal of Oncology</i> , 2010, 2010, 1-10.	0.6	18
46	Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer: A Phase II Trial of the Hellenic Cooperative Oncology Group. <i>Clinical Breast Cancer</i> , 2010, 10, 230-237.	1.1	17
47	Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck. <i>Anticancer Research</i> , 2009, 29, 529-38.	0.5	17
48	Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases. <i>Annals of Oncology</i> , 2012, 23, 2725-2730.	0.6	16
49	Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 307-321.	1.1	16
50	Profiling immunohistochemical expression of NOTCH1, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 603-614.	1.7	15
51	Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. <i>Journal of Translational Medicine</i> , 2015, 13, 171.	1.8	15
52	Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG). <i>Journal of Neuro-Oncology</i> , 2017, 134, 443-451.	1.4	15
53	Prognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG). <i>PLoS ONE</i> , 2013, 8, e70634.	1.1	15
54	Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation. <i>Anticancer Research</i> , 2006, 26, 4675-86.	0.5	15

#	ARTICLE	IF	CITATIONS
55	Solitary fibrous tumor of the tongue: case report and literature review. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2008, 37, 1067-1069.	0.7	14
56	Protein expression patterns of cell cycle regulators in operable breast cancer. <i>PLoS ONE</i> , 2017, 12, e0180489.	1.1	14
57	Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays. <i>Anticancer Research</i> , 2013, 33, 2139-45.	0.5	14
58	Molecular detection of <i>Helicobacter pylori</i> in a large Mediterranean river, by direct viable count fluorescent in situ hybridization (DVC-FISH). <i>Journal of Water and Health</i> , 2014, 12, 868-873.	1.1	13
59	alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies. <i>BMC Clinical Pathology</i> , 2014, 14, 28.	1.8	13
60	Prevalent somatic <i>BRCA1</i> mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe. <i>International Journal of Cancer</i> , 2018, 142, 66-80.	2.3	13
61	Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab. <i>Cancer Genomics and Proteomics</i> , 2018, 15, 461-471.	1.0	13
62	Opposite Prognostic Impact of Single PTEN-loss and <i>PIK3CA</i> Mutations in Early High-risk Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 195-206.	1.0	13
63	Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial. <i>PLoS ONE</i> , 2013, 8, e69256.	1.1	12
64	Dermoscopic predictors to discriminate between in situ and early invasive lentigo maligna melanoma: A retrospective observational study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 269-271.	0.6	11
65	Eccrine syringofibroadenoma treated with carbon dioxide laser. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 261-263.	0.6	9
66	HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 1231-1237.	0.8	9
67	p85 Protein Expression is Associated with Poor Survival in HER2-Positive Patients with Advanced Breast Cancer Treated with Trastuzumab. <i>Pathology and Oncology Research</i> , 2015, 21, 273-282.	0.9	9
68	Heart and lymphoma: An unusual case of secondary cardiac lymphoma manifested through presyncope and syncope episodes and atrial flutter. <i>Hellenic Journal of Cardiology</i> , 2018, 59, 182-185.	0.4	9
69	Renal Cell Carcinoma Antigen Expression in Primary Cutaneous Endocrine Mucinous Carcinomas: A Case Series of 14 Patients and Review of the Literature. <i>American Journal of Dermatopathology</i> , 2019, 41, 571-577.	0.3	9
70	Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials. <i>Clinical Breast Cancer</i> , 2018, 18, 53-62.e3.	1.1	8
71	Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome. <i>Clinical Breast Cancer</i> , 2019, 19, 113-125.e4.	1.1	8
72	Complete response of locally advanced basosquamous carcinoma to vismodegib in two patients. <i>European Journal of Dermatology</i> , 2019, 29, 102-104.	0.3	8

#	ARTICLE	IF	CITATIONS
73	Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers. <i>American Journal of Cancer Research</i> , 2018, 8, 2-15.	1.4	7
74	PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 1289-1301.	1.1	6
75	Crizotinib Failure in a <i>TPM4-ALK</i> "Rearranged Inflammatory Myofibroblastic Tumor With an Emerging <i>ALK</i> Kinase Domain Mutation. <i>JCO Precision Oncology</i> , 2017, 1, 1-7.	1.5	6
76	Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. <i>Medical Oncology</i> , 2018, 35, 101.	1.2	6
77	Protein and mRNA expression of notch pathway components in operable tumors of patients with laryngeal cancer. <i>Anticancer Research</i> , 2014, 34, 6495-503.	0.5	6
78	Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2016, 36, 2365-78.	0.5	6
79	Tubular Pyloric Gland Adenoma of the Left and Right Hepatic Ducts. <i>International Journal of Surgical Pathology</i> , 2016, 24, 347-352.	0.4	5
80	Clinicopathologically problematic melanocytic tumors: a case-based review. <i>Dermatology Practical and Conceptual</i> , 2018, 8, 306-313.	0.5	5
81	AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study. <i>Acta Oncologica</i> , 2021, 60, 785-793.	0.8	5
82	Dermoscopy of Spitz/Reed naevi and management. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 457-465.	0.8	5
83	Disease evolution and heterogeneity in bilateral breast cancer. <i>American Journal of Cancer Research</i> , 2016, 6, 2611-2630.	1.4	5
84	Immunohistochemical investigation of CD34 antigen in male breast carcinoma. <i>Clinical and Experimental Medicine</i> , 2007, 7, 122-126.	1.9	4
85	Prognostic significance of <i>WNT</i> and hedgehog pathway activation markers in cancer of unknown primary. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1145-1152.	1.7	4
86	Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study. <i>PLoS ONE</i> , 2018, 13, e0207707.	1.1	4
87	Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 277-290.	1.0	4
88	Dermoscopic predictors of melanoma arising in small- and medium-sized congenital nevi. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1703-1705.	0.6	4
89	Genetic Variations of <i>VEGFA</i> Gene Are Associated With Infiltration of Adjacent Tissues and the Clinical Outcome of Patients With Nasopharyngeal Carcinoma. <i>Anticancer Research</i> , 2020, 40, 677-688.	0.5	4
90	Aberrant <i>CCND1</i> copies and cyclin D1 mRNA expression do not result in the production of functional cyclin D1 protein in anaplastic large cell lymphoma. <i>Histology and Histopathology</i> , 2009, 24, 1035-48.	0.5	4

#	ARTICLE	IF	CITATIONS
91	In situdetection of hTERT variants in anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1639-1650.	0.6	3
92	Adjusting Breast Cancer Patient Prognosis with Non-HER2-Gene Patterns on Chromosome 17. <i>PLoS ONE</i> , 2014, 9, e103707.	1.1	3
93	Intact or Broken-apart RNA. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 60-70.	0.6	3
94	Thoracic duct cyst of posterior mediastinum: a "challenging" differential diagnosis. <i>Annals of Translational Medicine</i> , 2016, 4, 166-166.	0.7	3
95	Coincidence of thymoma and breast cancer and in a 56-year-old female patient. <i>Annals of Translational Medicine</i> , 2016, 4, 446-446.	0.7	3
96	Dermoscopy of poikilodermatous mycosis fungoides: A case escaping diagnosis for three decades. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2021, 37, 250-252.	0.7	3
97	Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 181-193.	1.0	2
98	Dermatoscopy of melanoma according to type, anatomic site and stage. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, .	0.1	2
99	Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study. <i>Histology and Histopathology</i> , 2015, 30, 1129-41.	0.5	2
100	Evaluation of the association of HER family members with efficacy of trastuzumab therapy in metastatic breast cancer. <i>Annals of Oncology</i> , 2016, 27, vi32.	0.6	1
101	Dermoscopy of papuloerythroderma of Ofuji. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2019, 35, 127-128.	0.7	1
102	Tumor infiltrating lymphocytes and hydrophobic amino acid changes in HER2-positive metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 592-592.	0.8	1
103	mRNA expression of specific HER ligands and their association with clinical outcome in patients with metastatic breast cancer treated with trastuzumab. <i>Oncology Letters</i> , 2021, 23, 23.	0.8	1
104	Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-based Regimens. <i>Cancer Research and Treatment</i> , 2021, , .	1.3	1
105	In response to Dr. Han's comments. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 245-245.	1.1	0
106	Potential Biomarkers for Response to Cetuximab in Patients with Metastatic Colorectal Cancer (MCRC). A Hellenic Cooperative Oncology Group Study. <i>Annals of Oncology</i> , 2012, 23, ix213.	0.6	0
107	Aberrant ALK1 Mrna Expression Patterns are Associated with Poor Prognosis in Non-Small Cell Lung Cancer (NSCLC) Patients. A Hellenic Cooperative Oncology Group Study. <i>Annals of Oncology</i> , 2012, 23, ix430-ix431.	0.6	0
108	Activation Status and Prognostic Significance of the Wnt/B Catenin and Hedgehog/Smoothed Signalling Pathways in Patients with Cancer of Unknown Primary (Cup): a Translational Research Study of the Hellenic Cooperative Oncology Group (Hecog). <i>Annals of Oncology</i> , 2014, 25, iv396.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Patient-private disease evolution and heterogeneity in bilateral breast cancer. <i>Annals of Oncology</i> , 2016, 27, vi54.	0.6	0
110	Mutation profiles of nasopharyngeal carcinomas in South-Eastern European patients. <i>Annals of Oncology</i> , 2016, 27, vi333.	0.6	0
111	Intrinsic tumor features underlying clinical subtype discordance in early breast cancer. <i>Annals of Oncology</i> , 2017, 28, v55-v56.	0.6	0
112	Abstract P2-09-15: TOP2A and DARPP32 Are Associated with Response to Trastuzumab-Based Treatment of HER2-Positive Advanced Breast Cancer (ABC). , 2010, , .		0
113	Abstract 5554: Tumor tissue dissection for gene expression assessments in translational research studies. , 2012, , .		0
114	ESR1 gene amplification and protein expression in 946 patients with resected breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) translational research study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 592-592.	0.8	0
115	In situ quantitative measurement of mRNA to predict response to trastuzumab in a cohort of metastatic breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 573-573.	0.8	0
116	Expression Profiling of 21 Biomolecules in Locally Advanced Nasopharyngeal Carcinomas (LA-NPC) of Caucasian Patients Treated with Chemotherapy or Chemo-Radiotherapy (CRT) in the Context of a Hellenic Cooperative Oncology Group Randomized Trial. <i>Annals of Oncology</i> , 2012, 23, ix337.	0.6	0
117	Abstract 1918: Genomic CNV testing on chromosome 17q genes reveals clinically relevant subtypes in breast cancer.. , 2013, , .		0
118	Abstract P3-05-15: TP53 mutation and nestin protein expression patterns affect the outcome of patients with triple negative breast cancer (TNBC). , 2013, , .		0
119	Evaluation of the prognostic value of p85 protein expression in HER2-positive and HER2-negative patients with advanced breast cancer treated with trastuzumab.. <i>Journal of Clinical Oncology</i> , 2014, 32, e11577-e11577.	0.8	0
120	Abstract P3-09-07: Prognostic value of immunophenotypically defined subtypes in patients treated with dose-dense sequential adjuvant chemotherapy in the trastuzumab era. A Hellenic Cooperative Oncology Group study. , 2015, , .		0
121	Multigene massively parallel sequencing (MPS) genomic patterns in bilateral breast cancers (BBC) to reveal patient-private disease evolution and heterogeneity.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22079-e22079.	0.8	0
122	Abstract P4-14-05: Genomic parameters affecting the outcome of patients with advanced breast cancer treated with trastuzumab. , 2016, , .		0
123	Abstract P5-08-50: Associations of MYC protein expression and gene status with breast cancer subtypes and outcome in patients treated with anthracycline-based adjuvant chemotherapy. , 2016, , .		0
124	Abstract P6-09-07: Mutation characteristics and tumor infiltrating lymphocytes in early and metastatic HER2-positive breast cancer. , 2017, , .		0
125	Lateral cervical lymph node metastasis from papillary thyroid cancer of undetected primary: a case report. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
126	Bortezomib induced purpuric rash. <i>Dermatologic Therapy</i> , 2020, 33, e13651.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Dermatoscopy of melanoma according to type, anatomic site and stage. Italian Journal of Dermatology and Venereology, 2021, 156, 274-288.	0.1	0